Genetiqpro Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.50 Cr
as on 09-01-2025
- Paid Up Capital ₹ 1.00 M
as on 09-01-2025
- Company Age 3 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 11.40 Cr
as on 09-01-2025
About Genetiqpro Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.50 Cr and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹11.40 Cr.
Lakshmipavani Botta, Bharathi Marasani, and Kanaka Golagani serve as directors at the Company.
- CIN/LLPIN
U24299AP2021PTC117827
- Company No.
117827
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Mar 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Genetiqpro Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bharathi Marasani  | Director | 24-Mar-2021 | Current |
| Lakshmipavani Botta | Director | 24-Mar-2021 | Current |
| Kanaka Golagani | Director | 24-Mar-2021 | Current |
Financial Performance of Genetiqpro Pharmaceuticals.
Enhance accessibility to Genetiqpro Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Genetiqpro Pharmaceuticals?
Unlock access to Genetiqpro Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Gm-Eco Logistics LlpActive 4 years 2 monthsLakshmipavani Botta and Kanaka Golagani are mutual person
- Gm-Eco Services LlpActive 3 years 8 months
Lakshmipavani Botta and Kanaka Golagani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 12 Oct 2022 | ₹11.40 Cr | Open |
How Many Employees Work at Genetiqpro Pharmaceuticals?
Genetiqpro Pharmaceuticals has a workforce of 19 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genetiqpro Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genetiqpro Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
